Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials.

@article{Latini2012Pentraxin3IC,
  title={Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials.},
  author={Roberto C. Latini and Lars Gullestad and Serge Masson and St{\aa}le Haugset Nymo and Thor Ueland and Ivan Cuccovillo and Mari H. V{\aa}rdal and Barbara Bottazzi and Alberto Mantovani and Donata Lucci and Nobuhito Masuda and Yukio Sudo and John Wikstrand and Gianni Tognoni and P{\aa}l Aukrust and Luigi T Tavazzi},
  journal={European journal of heart failure},
  year={2012},
  volume={14 9},
  pages={
          992-9
        }
}
AIMS Pentraxin-3 (PTX3) is a component of the humoral arm of innate immunity which can regulate inflammatory processes. Since the role of inflammation in the progression of chronic heart failure (HF) is debated, we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF. METHODS AND RESULTS Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 38 CITATIONS

Pentraxin 3 in Cardiovascular Disease

VIEW 5 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED

Associations between pentraxin 3 and severity of coronary artery disease

  • BMJ open
  • 2015
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials.

  • European journal of heart failure
  • 2013
VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED